Utilization patterns of extended-release naltrexone for alcohol dependence

Area of Science:

• Pharmacology
• Health Economics
• Addiction Medicine

Background:

• Alcohol use disorder (AUD) poses significant public health and economic burdens.
• Extended-release naltrexone (XR-NTX) is an option for AUD treatment, but its real-world utilization and cost-effectiveness require further study.

Purpose of the Study:

• To evaluate health plan member utilization of XR-NTX.
• To assess the impact of XR-NTX on alcohol-related hospitalizations and associated medical and pharmacy costs.
• To examine post-XR-NTX therapy outcomes and costs.

Main Methods:

• Retrospective analysis of health claims data.
• Inclusion of 48 members with continuous enrollment and a claim for XR-NTX (J2315) between July 2007 and December 2007.
• Evaluation of therapy duration, treatment gaps, and subsequent healthcare utilization and costs.

Main Results:

• Average XR-NTX therapy duration was 3 months.
• 58% of patients receiving 3+ months of therapy experienced treatment gaps.
• Significant reductions in alcohol-related hospitalizations, medical costs, and pharmacy costs were observed post-XR-NTX therapy.

Conclusions:

• XR-NTX therapy, even when used for less than 6 months, demonstrates significant cost-saving benefits.
• Abstinence from alcohol remains a challenge for patients after discontinuing XR-NTX therapy.
• Findings support the value of XR-NTX in managing alcohol use disorder and reducing healthcare expenditures.